METHOD AND COMPOSITIONS FOR TOPICAL APPLICATION OF TOCOTRIENOL TO THE SKIN

Abstract: A method for the prevention and/or treatment of skin or hair damage, particularly inflammation and aging of skin and hair damage from sunlight and chemicals, in which a tocotrienol, a derivative thereof or a vitamin E preparation enriched with tocotrienol or a tocotrienol derivative, is topically applied to the exposed or affected skin or hair areas. A fat-soluble fatty acid ester of ascorbic acid such as palmityl ascorbate is preferably applied with the tocotrienol in association with a dermatologically acceptable carrier.

Description: METHOD AND COMPOSITIONS FOR TOPICAL APPLICATION OF TOCOTRIENOL TO THE SKIN DESCRIPTION Related Application Data This is a continuation-in-part of co-pending U.S. Pat. Application Serial No. 08/003,603, filed January 13, 5 1993. Technical Field The present invention relates to the topical ap¬ plication to the skin or hair of active agents, and/or preparations containing them, for the prevention and/or 0 treatment of damage to skin, particularly for the treat¬ ment or prevention of inflammatory and aging effects, and hair, particularly for sunlight and chemical damage, using tocotrienols. Background Art 5 Vitamin E is a fat-soluble vitamin necessary in the diet of many species for normal reproduction, normal development of muscles, normal resistance of erythrocytes to hemolysis, and various other biochemical functions. The most widely accepted function of vitamin E is an an 0 antioxidant, protecting polyunsaturated fatty acids in membranes and other cellular structures from attack by free radicals. Vitamin E occurs in cereals (especially wheat germ and corn) , sunflower seed, rapeseed, soybean oil, alfalfa, lettuce, egg yolk, and beef liver, and consists primarily of three molecular species of tocol derivatives, the alpha-, beta- and gamma- tocopherols, of which alpha-tocopherol is most important because it has the widest distribution and greatest biological activity. Other tocopherols have been found in nature, in¬ cluding gamma-, eta-, zeta 2 , zeta L - and epsilon-tocopher¬ ol. The last two species, which occur in cereal grains, have unsaturated hydrocarbon tails and have been recently called tocotrienols (denoted alpha- and beta-tocotrienol, respectively) because each has three double bonds in the side chain, and this nomenclature distinguishes them from tocopherols bearing saturated tails. Gamma-tocopherol is claimed to be the most potent antioxidant of any tocoph¬ erol species ( The Merck Index, 11th ed. , 1989, entries 9417 to 9423 and 9931) , but activity appears to be depen¬ dent on the system used for measurement. .Thus, in the in vi tro systems of Burton, G. ., et al . , J. Am. Che . Soc . 107 : 7073-7065 (1985), for example, alpha-tocopherol was the most powerful antioxidant. The antioxidant function of vitamin E per se is localized in the chromanol nucleus, where the phenolic hydroxy group donates a hydrogen atom to quench lipid radicals ibid., and Serbinova, E., et al., Free Radical Biology & Med . , 10 : 263-275 (1991)) . The antioxidant potency of vitamin E is determined by the efficiency of the tocopherol in scavenging radicals and by the reactiv¬ ity of the chromanoxyl radical formed in further propaga¬ tion of lipid peroxidation or in the regeneration of the tocopherol due to interaction of the chromanoxyl radical with reductants; the latter does not propagate lipid peroxidation. In homogenous solutions, the rate constants of the reaction between the chromanol nucleus and radicals do not depend upon the length or unsaturation of the tocoph- erol hydrocarbon tails, but mainly depend on the number of methyl groups in the benzene ring of the chromanol nucleus (Burton, G.W. , et al . , cited above). Similarly, the reactivity of the chromanoxyl radical is mainly de- ter ined by hindering effects of the methyl groups. The situation is more complex in heterogenous mem¬ brane systems, however, where vitamin E appears to owe its antioxidant potency not solely to the chemistry of the tocopherol molecule but also to its mobility and accessibility within the membrane (Serbinova, cited above) . In some systems, tocotrienols appear to have higher antioxidant activity ( ibid. ) . However, in others, direct comparisons of antioxidant efficiency of tocopher¬ ols having saturated tails with tocotrienols did not demonstrate decisive differences in the activities of these two forms of vitamin E (ibid, and Nakano, M., et al . , Biochim. Biophys . Acta 619 : 274-286 (1980)) . The antioxidant activity of tocotrienol prevents free radical damage to cells and cell components. Free radical damage is most evident in cellular membranes because of the density of the molecular structure of the membranes. It is currently hypothesized that cell mem¬ brane aging leads to all of the various cellular changes seen in aging, such as decreased RNA production, de- creased protein production, and faulty enzyme action. Inflammation in skin is mediated by several active chemicals and metabolites of arachidonic acid. Arachi¬ donic acid is oxidized by cyclo-oxygenase and lipoxygen- ase to active metabolites such as the leukotrienes and 5- and 12- hydroxyeicosatetraenoic acid (HETES) . Within the arachidonic acid cascade, many free radicals are generat¬ ed, which both perpetuate and magnify the inflammatory cascade, resulting in skin damage and manifested clini¬ cally as erythema. Early suggestions for dealing with erythema and aging effects in skin were predominantly aimed at lubri¬ cations and emollients through use of topical composi¬ tions containing soothing agents, e . g. , as exemplified by commercial hand lotion products and the like. More re¬ cently, attention has been directed to agents which ad¬ dress the underlying processes involved in skin damage, such as the free radical generation processes. In this regard, investigations have been made with respect to the antioxidants vitamin E and vitamin C to quench free radi¬ cals on the surface of the skin and to protect lipid membranes intracellularly (Wilson, R. , Drug and Cosmetic Industry, 32-34, 38, and 68, August 1992) . Damage to hair, particularly damage caused by excessive exposure to sunlight or harsh chemicals, is also mediated in part by oxidation of keratin. Tradi¬ tional remedies typically add oil in a conditioner or shampoo to ameloriate the hair's dryness and brittleness. It would be desirable to have alternative topical compositions for anti-inflammatory and anti-aging effects observed in skin, particularly compositions that are efficient in free radical scavenging in membranes. It would also be desirable to have hair treatments that treat the actual cause of hair damage, rather than merely assuage its effects. Disclosure of the Invention The primary object of this invention is to provide methods and compositions for prevention and/or treatment of skin inflammation, aging, and other skin damage and hair damage mediated by free radicals. It is a more particular object of the invention to provide a preventive regimen and/or therapy based upon topical application to exposed or affected skin areas or damaged hair of an active agent or precursor thereof, preferably in association with a dermatologically accept¬ able carrier or vehicle. These and other objects are accomplished by the present invention, which provides a method and composi¬ tion for the prevention and/or treatment of skin inflam¬ mation, aging and other skin damage and hair damage, which comprises topical application to the exposed or affected skin sites of an effective amount of one or more tocotrienols or derivatives thereof or vitamin E composi¬ tions enriched with tocotrienols or tocotrienol deriva¬ tives. Reductants such as alpha-hydroxy acids, ascorbic acid and the like, particularly fat-soluble fatty acid esters of ascorbic acid, can, optionally, be utilized along with the tocotrienol as a means for yet further enhancing the efficacy of the therapeutic or prophylactic treatment. In the preferred practice of the invention, the tocotrienol (or derivative) or tocotrienol-enriched vita¬ min E is applied in admixture with a dermatologically acceptable carrier or vehicle ( e. g. , as a lotion, cream, ointment, soap, or the like) so as to facilitate topical application and, in some cases, provide additional thera- peutic effects as might be brought about, e . g. , by mois¬ turizing of the affected skin or hair areas. As noted, reductants, particularly ascorbyl fatty acid esters, e . g. , ascorbyl palmitate, can be advantageously included in the compositions. The amount of tocotrienol or derivative thereof ( hereinafter referred to collectively as tocotrienol for ease of reference) necessary to bring about enhanced prevention and/or therapeutic treatment of skin or hair damage is not fixed per se, and necessarily is dependent upon the identity and form of tocotrienol employed, the concentration of tocotrienol when employed as a tocotrie¬ nol-enriched vitamin E preparation and/or with a carrier, the amount and type of any additional reductant such as ascorbyl fatty acid ester, when employed with the toco¬ trienol, the user's skin or hair type, and, where pres¬ ent, the severity and extent of the patient's pathologi¬ cal skin or hair condition. Generally, the tocotrienol or composition containing it is topically applied in effective amounts to skin areas which have been damaged or aged, or which are susceptible to damage, because of inflammation or aging, or hair that is dry and brittle. Best Modes for Carrying Out the Invention This invention is based upon the finding that tocotrienols or tocotrienol-enriched vitamin E composi¬ tions, especially tocotrienols or tocotrienol-enriched vitamin E in combination with a reductant, such as ascor¬ byl fatty acid ester, augment the efficacy of topical compositions for inflammation, aging and other skin dam- age, including compositions that contain conventional vitamin E. Tocotrienol also augments the efficacy of hair compositions. As used herein, the term "tocopherol" encompasses vitamin E derivatives bearing saturated hydrocarbon tails having the following general formula: and includes both natural alpha-, beta-, gamma-, and delta- tocopherol as well as synthetic derivatives and mixtures thereof. The term "tococrienol" encompasses their counterparts bearing unsacurated tails, including, but not limited to, alpha-, beta-, gamma-, and delta- tocotrienols, desmethyl-tocotrienol, didesmethyl-tocotri¬ enol, occurring in sunflower seeds, vegetable oils, bar¬ ley, brewer's grains, oats, and African violets, which have three double bonds in the side chain at the 3', 7' and 11' positions in the formula set out above, their synthetic counterparts, their counterparts having methyl¬ ated or demethylated chroman rings, and mixtures thereof. The double bonds may be cis or trans or mixtures thereof. Tocotrienol or tocotrienol derivatives or mixtures thereof are employed in this invention either in the sub¬ stantial absence of tocopherols wherein the compositions contain essentially no tocopherol or in tocotrienol-en¬ riched vitamin E preparations. By "tocotrienol-enriched vitamin E preparations" is meant vitamin E preparations containing a greater concentration of tocotrienol than that found in preparations isolated from natural sources. These tocotrienol-enriched vitamin E preparations can, for example, be naturally-occurring vitamin E prepara- tions to which tocotrienol has been added or naturally occurring vitamin E preparations from which a portion of tocopherol has been removed. Preferred vitamin E preparations are isolated from natural sources, but synthetic preparations may also be employed as well as mixtures of natural and synthetic vitamin E. Tocotrienol-enriched vitamin E preparations may be obtained by fractionating vitamin E preparations to remove a portion of tocopherols and recover a prepara¬ tion more highly concentrated in tocotrienol. Many tocotrienols useful for the practice of the invention are natural products isolated, for example, from wheat germ oil, bran, or palm oil using high perfor¬ mance liquid chromatography, or isolated by alcohol ex¬ traction and/or molecular distillation from barley, brew- er's grain or oats. As used herein, the term "tocotrie¬ nols" includes tocotrienol-rich-fractions obtained from these natural products as well as the pure compounds. D-alpha-tocotrienol is especially preferred in one em- bodiment. As with other vitamin E preparations, tocotrienol or tocotrienol-enriched preparations include those con¬ taining tocotrienol and, in some cases, tocopherol deriv¬ atives, particularly stabilized derivatives. These typi- cally include derivatives related to the phenolic hydrox- yl functionality, i.e., wherein it is acylated with an organic acid to form an ester. Examples of such stabi¬ lized tocotrienols include, but are not limited to, toco¬ trienol acetate, tocotrienol succinate, and mixtures thereof. However, the derivatives may also include those involving other reactive groups known to those skilled in the art. Where tocotrienol derivatives are employed, they must be functionally equivalent to tocotrienol. Preferred derivatives contain both the chromanol nucleus and three double bonds in the hydrocarbon tail. Vitamin E derivatives generally vary in consisten¬ cy from viscous oils to oily liquids. Therefore, toco¬ trienols or tocotrienol-enriched vitamin E preparations can be applied neat to skin areas or hair subject to damage or already damaged. It is an advantage of the invention that the active compound is oily so that it physically contributes to the lubrication and soothing of affected skin areas, and to the replacement of natural oils on hair. However, only effective amounts of tocotrienols are needed to prevent or treat skin or hair damage, so generally topical application to exposed or affected skin sites is accomplished in association with a carrier, and particularly one in which the active ingredient is solu- ble per se or is effectively solubilized ( e . g. , as an emulsion or microemulsion) . It is necessary that the carrier be inert in the sense of not bringing about a deactivation of the tocotrienol or derivative, and in the sense of not bringing about any adverse effect on the skin areas to which it is applied. Suitable carriers include water, alcohols, oils and the like, chosen for their ability to dissolve or disperse the active ingredient at concentrations of ac- tive ingredient most suitable for use in the preventive or therapeutic treatment. Generally, even low concentra¬ tions of active ingredient in a carrier will be suitable, requiring only that more frequent topical application be resorted to. As a practical matter, however, to avoid the need for repeated application, it is desirable that the topically applied composition (i . e . , tocotrienol or derivative or tocotrienol-enriched vitamin E preparation plus carrier) be formulated to typically contain from about 0.025% to about 10% by weight, more narrowly about 0.025% to about 5% by weight, of the active ingredient. Some embodiments such as those for prophylaxis and compo¬ sitions that remain on affected skin or hair for some time contain from about 0.025% to about 0.25% by weight, more narrowly from about 0.025% to 0.1% by weight toco- trienol; others contain from about 0.05% to about 0.2%, more narrowly from about 0.05% to about 0.1% tocotrienol. Embodiments for treatment of more severe damage may con¬ tain from about 0.5% to about 3% by weight, more narrowly from about 0.5% to 1.5% by weight tocotrienol. Some em- bodiments contain at least about 3% by weight, typically at least about 3% to about 10% by weight, of the active ingredient. Carriers will accordingly be chosen which can solubilize or disperse the active ingredient at such concentrations. While the carrier for the tocotrienol or deriva¬ tive or tocotrienol-enriched vitamin E preparation can consist of a relatively simple solvent or dispersant such as water or oils, it is generally preferred that the carrier comprise a composition more conducive to topical application, and particularly one which will form a film or layer on the skin or hair to which it is applied so as to localize the application and provide some resistance to washing off by immersion in water or by perspiration and/or aid in the percutaneous delivery of the active agent. Many such compositions are known in the art, and can take the form of lotions, creams, gels or even solid compositions (e.g., stick-form preparations) . Typical compositions include lotions containing water and/or alcohols and emollients such as hydrocarbon oils and waxes, silicone oils, vegetable, animal or marine fats or oils, glyceride derivatives, fatty acids.or fatty acid esters or alcohols or alcohol ethers, lecithin, lanolin and derivatives, polyhydric alcohols or esters, wax es- ters, sterols, phospholipids and the like, and generally also emulsifiers (nonionic, cationic or anionic) , al¬ though some of the emollients inherently possess emulsi¬ fying properties. These same general ingredients can be formulated into a cream rather than a lotion, or into gels, or into solid sticks by utilization of different proportions of the ingredients and/or by inclusion of thickening agents such as gums or other forms of hydro- phillic colloids. Such compositions are referred to herein as dermatologically acceptable carriers. Carriers for hair compositions are also dermatolo¬ gically acceptable so that the scalp is not injured. For damaged hair, tocotrienol is typically added to a sham¬ poo, conditioner, hair cream, or hair spray or gel. Many of these compositons contain enriched palm oil . Toco- trienol is an excellent choice for these compositions as it not only acts as an antioxidant, but (as has been mentioned) it also replaces the natural hair oils. Lev¬ els of tocotrienol in hair compositions vary in different embodiments as set out above, and preferably vary from about 0.025% to about 1%. Treatments of extreme condi- tions, however, require more active ingredient. Many preferred embodiments of this invention con¬ tain a reductant in addition to tocotrienol. Some em¬ bodiments, for example, employ alpha-hydroxy acids such as glycolic acid, hydroxymethylglycolic acid, lactic acid, glucuronic acid, galacturonic acid, gluconic acid, glucoheptonic acid, alpha-hydroxybutyric acid, alpha-hy- droxyisobutyric acid, alpha-hydroxyvaleric acid, al- pha-hydroxyisovaleric acid, alpha-hydroxycaproic acid, alpha-isocaproic acid, tartronic acid, tartaric acid, malic acid, hydroxyglutaric acid, hydroxyadipic acid, hydroxypimelic acid, muric acid, citric acid, isocitric acid, saccharic acid, dihydroxymaleic acid, dihydroxy- tartaric acid, and dihydroxyfumaric acid or derivatives of hydroxy acids such as pyruvic acid, methyl pyruvate, ethyl pyruvate, isopropyl pyruvate, benzoylformic acid, methyl benzoylformate, and ethyl benzoylformate. Other embodiments employ ascorbic acid as a reduc¬ tant, most preferably fat-soluble fatty acid esters of ascorbic acid (vitamin C) in addition to tocotrienol. The more oxidation-resistant saturated fatty acid esters of ascorbic acid are preferred, including, but not limit¬ ed to, ascorbyl laurate, ascorbyl myristate, ascorbyl palmitate, ascorbyl stearate, and ascorbyl behenate. As denoted herein, where fatty acid esters are described, e.g., ascorbyl stearate, compositions having predominant¬ ly that ester, e.g., predominantly stearate, are includ¬ ed. The esters may be prepared using hydrogenated oils or fats, or fractions thereof, and contain small amounts of another ester. Ascorbyl stearate prepared using can- ola, for example, commonly contain about 4% ascorbyl palmitate. The combination of tocotrienol or tocotrienol-en- riched vitamin E preparations and a fat-soluble vitamin C fatty acid ester in a dermatologically acceptable carrier is especially advantageous in compositions because toco¬ trienol augments the efficacy of the composition. The combination readily solubilizes in the lipid-rich layers of the skin and together scavenge free radicals involved in aging, inflammation, and other skin damage (more fully discussed below) . As has been mentioned, it also con¬ tributes to the replacement of natural oils in hair com¬ positions. The effectiveness of tocotrienols and tocotrienol derivatives, especially when employed in combination with a reductant such as ascorbyl fatty acid esters, can be postulated as resulting from the antioxidant properties of tocotrienol per se, which properties are unexpectedly retained and provided to a high degree when used in con¬ cert with ascorbyl fatty acid esters when these are de¬ livered in combination to the skin in an extremely effec¬ tive manner in an oil phase. The mechanism of the effect is not well understood, but may be related to the an¬ ti-oxidant properties of the active compounds and/or their interference with chemical reactions. In terms of a possible explanation for the effec- tiveness of tocotrienol in the prevention or treatment of damage to the skin, it is noted that tocotrienol, as an antioxidant, can scavenge free radicals such as the oxy¬ gen radicals created by exposure of skin cells to damage, as well as the generation of free radicals produced by normal metabolism extracellularly and intracellularly. Alpha-tocotrienol, as a powerful antioxidant concentrated in cell membranes, can lessen erythema by the mechanism of free radical scavenging and chain breaking chemical reactions. Ascorbic acid is a powerful reducing agent that can prevent oxidative damage and regenerate chroman¬ oxyl radicals formed as vitamin E derivatives scavenge radicals, reforming vitamin E that can scavenge more radicals. Preferred embodiments of this invention har¬ ness this synergestic effect. In addition, ascorbic acid can increase cyclo-oxy- genase activity in human cells. Cyclo-oxygenase is a key enzyme in the oxidation of arachadonic acid, which leads the formation of prostaglandins which in turn mediate in¬ flammation. Because cell aging is the result of free radical damage, it is apparent that tocotrienols are also effec¬ tive in the prevention of cell aging. The tocotrienols, with their unsaturated hydrocarbon chain, disperse within cell membranes, acting as a free radical scavenger and neutralizer, and prevent the cross-linking of cell mem¬ branes that is seen in the aging process. Once the cell membranes are cross-linked, the permeability of cell membranes increases, causing an inefficient exchange of nutrients and waste products within the cell. The de¬ creased cell permeability results in increased ionic concentration of potassium, which then causes decreased messenger RNA production. The increased ionic concentra- tion also interferes with enzyme activity, as enzymes are very much dependent on ionic concentration for their action. In addition to decreased production of RNA, there is a marked decrease in the production of protein with aging, and therefore the cell cannot repair itself. The altered cellular membranes prevent removal of waste prod¬ ucts in the cell, such as lipofucin, which is a histolog- ic characteristic of all aging cells. Tocotrienol, by preventing free radical damage to cell membranes, and preventing decreased permeability to cells, can theoreti¬ cally prevent aging of the cell by maintaining proper ionic concentration, proper disposal of waste products, and efficient protein and RNA production. Topical appli- cation of tocotrienols to skin can prevent cell aging. The method of the present invention is particular¬ ly useful for the prevention of skin damage which may result from exposure to ultraviolet radiation, but, based upon the likely mechanism of action, also is useful in general for treatment of any radiation-induced skin dam¬ age, particularly that associated with free radical re¬ lated damage. As such, the topical application of toco¬ trienol according to the invention can also be effective for chronic administration to prevent the free radical damage seen in the natural aging process of the skin and the free radical damage caused by chronic exposure to sunlight. Tocotrienol or tocotrienol and ascorbyl fatty acid esters can thus be added to dermatological creams and emollients as well as to commercial suncreens to enhance their anti-aging and anti-cancer activity. It is an advantage of the invention that, because of the efficiency of free radical scavenging and other biochemical mechanisms involved after application of tocotrienol or tocotrienol and ascorbic acid fatty acid ester combinations to skin, compositions of the invention exhibit efficacy when applied to a variety of skin dam¬ aged conditions, including dry skin, psoriasis, and der¬ matitis (contact, irritant, and allergic) . Compositions of the invention can also be used as a treatment after burn. Tocotrienol compositions also ameloriate keratin oxidation by the same mechanisms described above for collagen. In hair compositions, its physical properties also enhance oil replacement in hair damaged by excessive sunlight or harsh chemicals. Having described the invention with reference to particular compositions, theories of effectiveness, and the like, it will be apparent to those of skill in the art that it is not intended that the invention be limited by such illustrative embodiments or mechanisms, and that modifications can be made without departing from the scope or spirit of the invention, as defined by the ap- pended claims. It is intended that all such obvious modifications and variations be included within the scope of the present invention as defined in the appended claims. The claims are meant to cover the claimed compo¬ nents and steps in any sequence which is effective to meet the objectives there intended, unless the context specifically indicates the contrary. All references cited herein are expressly incorpo¬ rated herein in their entireties by reference.

Claims: CLAIMS 1. A method for treating or preventing skin damage, said method comprising topically applying to skin areas sub¬ ject to such damage an effective amount of an active compound selected from the group consisting of toco- trienols in the substantial absence of tocopherols, de¬ rivatives of tocotrienols in the substantial absence of tocopherols, vitamin E preparations enriched with toco¬ trienols, vitamin E preparations enriched with tocotrien¬ ol derivatives and mixtures thereof. 2. A method according to claim 1 wherein the active com¬ pound is a tocotrienol selected from the group consisting of alpha-tocotrienol, beta-tocotrienol, gamma-tocotrien¬ ol, delta-tocotrienol, desmethyl-tocotrienol, didesmeth- yl-tocotrienol, and mixtures thereof. 3. A method according to claim 1 wherein said effective amount is appied as a composition further comprising a reductant. 4. A method according to claim 3 wherein said reductant is a fat-soluble fatty acid ester of ascorbic acid. 5. A method according to claim 4 wherein said fat-sol¬ uble fatty acid ester of ascorbic acid is selected from the group consisting of ascorbyl palmitate, ascorbyl laurate, ascorbyl myristate, ascorbyl stearate, and mix- tures thereof. 6. A method according to claim 5 wherein said fat-sol¬ uble fatty acid ester of ascorbic acid is ascorbyl palmi¬ tate. 7. A method according to claim 1 wherein the composition comprises about 0.025% to about 10% by weight tocotrienol. 8. A method according to claim 1 wherein said skin dam¬ age is selected from the group consisting of inflamma¬ tion, dry skin, aging, psoriasis, dermatitis, and burn. 9. A method according to claim 1 wherein the effective amount comprises an amount effective, in the lipid-rich layers of the skin, to scavenge free radicals in the skin. 10. A method for the treatment or prevention of hair damage, said treatment comprising topically applying to the affected hair an effective amount of a composition comprised of a dermatologically acceptable carrier and a tocotrienol composition selected from the group consist¬ ing of (a) a tocotrienol selected from the group consist¬ ing of tocotrienols, derivatives of tocotrienols, and mixtures thereof, containing essentially no tocopherols bearing saturated hydrocarbon tails, (b) a vitamin E preparation enriched with a toco¬ trienol selected from the group consisting of toco¬ trienols, derivatives of tocotrienols, and (c) mixtures thereof. 11. A method according to claim 10 wherein the composi¬ tion further comprises a fa -soluble fatty acid ester of ascorbic acid selected from the group consisting of as¬ corbyl palmitate, ascorbyl laurate, ascorbyl myristate, ascorbyl stearate, and mixtures thereof. 12. A method according to claim 11 wherein the toco¬ trienol is selected from the group consisting of al¬ pha-tocotrienol, beta-tocotrienol, gamma-tocotrienol, delta-tocotrienol, desmethyl-tocotrienol, didesmethyl- tocotrienol, and mixtures thereof. 13. A method according to claim 12 wherein the tocotrie¬ nol is alpha-tocotrienol. 14. In a dermatological composition for treatment of in¬ flammation or aging of the skin in a dermatologically ac¬ ceptable carrier, an improvement wherein, to augment the efficacy of the composition, said composition further comprises a tocotrienol composition selected from the group consisting of tocotrienols which contain essential¬ ly no tocopherol, tocotrienol derivatives which contain essentially no tocopherol, vitamin E preparations en¬ riched with tocotrienols, vitamin E preparations enriched with tocotrienol derivatives and mixtures thereof. 15. An improvement according to claim 14 wherein said tocotrienol is selected from the group consisting of alpha-tocotrienol, beta-tocotrienol, gamma-tocotrienol, and delta-tocotrienol. 16. An improvement according to claim 15 wherein said tocotrienol is D-alpha-tocotrienol. 17. An improvement according to claim 14 wherein said tocotrienol is present in said composition in amounts effective to scavenge free radicals from lipid-rich lay¬ ers of the skin. 18. An improvement according to claim 15 wherein the composition further comprises a fat-soluble fatty acid ester of ascorbic acid selected from the group consisting of ascorbyl palmitate, ascorbyl laurate, ascorbyl myris- tate, ascorbyl stearate, and mixtures thereof. 19. An improvement according to claim 18 wherein said tocotrienol is present in said composition in amounts effective to scavenge free radicals from lipid-rich lay¬ ers of the skin. 20. An improvement according to claim 14 wherein said composition comprises about 0.025% to about 3% by weight tocotrienol.

Inventors: PERRICONE NICHOLAS V, PERRICONE, NICHOLAS, V.
Applicants: PERRICONE NICHOLAS V, PERRICONE, NICHOLAS, V.
Application year: 1995
Main classification: A61K31
IPC codes: A61K8, A61K31, A61Q5, A61Q17, A61Q19